Press Releases

Marketing campaign includes the brand's first-ever commercial spot introducing women to a birth control that puts them in control of their body, their sex life, and their pregnancy prevention.

Collaboration will provide resources about Phexxi® contraceptive vaginal gel to oncologists, pharmacists and associated healthcare providers

Evofem honored amongst best companies globally for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi®

Approximately 25 Million Adult Women Covered by Medicaid

High Level of Interest from Clinical Sites Seeking to Participate in EVOGUARD Trial

Launched Phexxi™ (lactic acid, citric acid, potassium bitartrate) in U.S. for Hormone-free Contraception

-- Conference Call Scheduled for 5:00 p.m. ET --

- Live moderated video webcast discussion with members of Evofem management and Key Opinion Leader Patty Cason, RN, MS, FNP-BC, on Thursday, October 29th at 2:00 p.m. ET -

- Company plans to initiate Phase 3 STI trial by the end of 2020 -

- A First-in-Class Vaginal pH Modulator Designed for Use "In-the-Moment" -

- Advancing Precommercial Activities in Preparation for Phexxi™ Commercial Launch in September 2020 -

-- Conference Call Scheduled for 11:00 a.m. EDT --